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part of this study, all samples from ma-
laria case-patients identiﬁ  ed  through 
clinical diagnosis were subject to a 
Paracheck-Pf immunoassay test (Or-
chid Biomedical Systems, Verna, Goa, 
India). Results indicated that, at the 
peak of the apparent malaria outbreak, 
the percentage of samples from clini-
cally diagnosed cases that produced a 
positive diagnostic test was as low as 
4% (Figure, panel B). These results 
are unlikely to reﬂ  ect poor diagnostic 
performance of the testing (6); febrile 
illness other than malaria was likely 
the cause of the outbreak.
Recent experiences in Kabale 
also highlight the potentially unwieldy 
nature of indoor residual spraying 
campaigns in the absence of spatial 
targeting. In Kabale, a district-wide 
spraying campaign supported by the 
US President’s Malaria Initiative (7) 
was planned for the 2006 transmission 
season. However, shortages of trained 
personnel and other institutional de-
lays meant that spraying could not 
begin until the third week of June, by 
which time the epidemic had peaked 
(and densities of vector mosquitoes 
had presumably begun to fall). By 
July 17, <50% of the targeted struc-
tures had been sprayed. In the future, 
careful targeting of spraying to areas 
of highest epidemic risk might lead to 
more timely completion of spraying 
activities. It might also be beneﬁ  cial 
to create special spray teams that can 
respond quickly to speciﬁ  c alerts.
Recent experiences in Kabale 
have underlined the potential value 
of simple monitoring tools for early 
detection of epidemics but have also 
shown potential barriers to effective 
epidemic control. Our ﬁ  ndings high-
light the need to build systems that 
improve routine collection of data 
on parasitologically conﬁ  rmed  cases 
of malaria and allow rapid investiga-
tion of anomalies in incoming clinical 
data. It is equally important to develop 
procedures that translate early warn-
ing information into timely decisions 
concerning which epidemic control 
measures to use and how best to target 
them (8). Without these procedures, 
the value of early detection will be     
seriously undermined.
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Extensively 
Drug-resistant 
Tuberculosis, Italy 
and Germany 
To the Editor: Twenty-three 
countries have reported >1 case of 
extensively drug-resistant tubercu-
losis (XDR TB) (1); however, in-
formation about XDR TB is still in-
complete. In particular, the response 
of XDR TB to treatment in countries 
with low incidence is not known. We 
compared mortality rates from XDR 
TB with those from multidrug-resis-
tant (MDR) TB.
We analyzed data from all cul-
ture-conﬁ   rmed TB cases diagnosed 
during 2003–2006 by the TB clinical 
reference centers in Italy (Sondalo, 
Milan, Rome) and Germany (Borstel, 
Grosshansdorf, Bad-Lippspringe) and 
reviewed original clinical records. 
Drug susceptibility testing for ﬁ  rst- 
and second-line anti-TB drugs was 
performed according to World Health 
Organization (WHO) recommenda-
tions by quality-assured  laboratories 
and retested at WHO Supranational 
Reference Laboratories (Rome/Milan; 
Borstel) (2–4).
XDR TB was deﬁ   ned as resis-
tance to at least rifampin and isoniazid 
(MDR TB deﬁ   nition) in addition to LETTERS
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any ﬂ  uoroquinolone and >1 of 3 in-
jectable anti-TB drugs (capreomycin, 
kanamycin, amikacin) (3). Character-
istics of MDR TB and XDR TB cases 
were compared by χ2 test (categorical 
variables), Student t test (admission 
days), and Kaplan-Maier curve (spu-
tum smear, culture conversion), where 
appropriate.
Of 2,888 culture-positive TB 
cases analyzed (Italy 2,140, Germany 
748), 126 (4.4%) were MDR (Italy 83, 
Germany 43) and 11 (0.4%) were XDR 
(Italy 8, Germany 3). We estimate that 
the TB cases analyzed represent 24% 
of culture-positive cases reported in 
Italy (69.7% of MDR) and 4.2% of 
those reported in Germany (12.6% 
of MDR). XDR TB was diagnosed in 
each year of the study. All 11 XDR TB 
patients were receiving retreatment, 
and of the 126 MDR TB patients, 74 
(58.7%) were receiving retreatment. 
All XDR TB patients were HIV sero-
negative; and of 109 MDR TB patients 
tested for HIV, 10 (9.2%) were HIV 
seropositive. Details about previous 
treatment regimens, drug resistance, 
and duration of treatment of XDR TB 
patients are summarized in the online 
Appendix Table (available from www.
cdc.gov/EID/content/13/5/780_appT.
htm). XDR TB patients were sig-
niﬁ  cantly more likely than MDR TB 
patients to be resistant to all ﬁ  rst-line 
drugs (8/11 vs. 36/126, p<0.005); 2 
of these patients were resistant to all 
tested drugs (online Appendix Table).
In Germany, nonnationals ac-
counted for 95.3% (41/43) of MDR
TB cases and 100% (3 of 3) of XDR 
TB cases (all from the former Soviet 
Union); in Italy, they accounted for 
72.3% (60/83) and 50% (4/8), re-
spectively (p<0.001). Of 126 patients 
with MDR, 8 (6.3%) died, 45 (35.7%) 
were treated successfully, 67 (53.2%) 
were still receiving treatment (after 
achieving bacteriologic conversion, 
radiologic and clinical improvement, 
or both), and 6 defaulted (4.8%). Of 
11 patients with XDR, 4 (36.4%) 
died and 7 (63.6%) were still receiv-
ing treatment. Compared with MDR 
TB patients, XDR TB patients had a 
5-fold higher risk for death (relative 
risk 5.45; 95% conﬁ  dence  interval 
1.95–15.27; p<0.01) and required lon-
ger hospitalization (mean ± SD 241.2 
± 177.0 vs. 99.1 ± 85.9 days; p<0.001) 
and longer treatment durations (30.3 ± 
29.4 vs. 15.0 ± 23.8 months; p<0.05). 
Smear and culture conversions were 
observed for 4 XDR TB patients com-
pared with 102 MDR TB patients 
(smear median 110 vs. 41 days; cul-
ture median 97.5 vs. 58 days, respec-
tively); time to smear and culture con-
version signiﬁ  cantly differed between 
the 2 groups  (p<0.01). A higher per-
centage of XDR TB than MDR TB 
patients had received previous anti-
TB treatment (100% [11/11] vs. 59% 
[74/126], respectively, p<0.01) and 
were >45 years of age (64% [7/11] and 
23% [29/126], respectively, p<0.01). 
Radiologic patterns of the thorax did 
not differ between XDR TB and MDR 
TB patients. In the overall sample, the 
only variable signiﬁ  cantly associated 
with death (other than XDR TB status) 
was immigrant status (p<0.01). The 
association between XDR TB status 
and risk for death remained signiﬁ  cant 
after stratiﬁ  cation by immigrant status 
(p<0.05).
Our  ﬁ   ndings suggest that mis-
management of TB cases plays a ma-
jor role in emergence of the problem 
in Europe (along with suboptimal in-
fection control in congregate settings) 
(5), while in high HIV-prevalence 
settings (e.g., South Africa) XDR TB 
was mainly observed in patients never 
treated previously (6). Mortality rates 
among MDR TB patients treated in ref-
erence centers (6.3%) were lower than 
the rate observed in a previous study 
in general hospitals in Italy (8.7%) (5), 
although a proportion of our MDR TB 
patients are still completing treatment. 
This difference  in rates is probably 
due to better management of MDR in 
the reference centers. Because of the 
high proportion of XDR TB patients 
still receiving treatment, further fol-
low-up is necessary to assess potential 
for cure. The clinical relevance of re-
sistance to all ﬁ  rst-line drugs or other 
factors (e.g., delayed or inadequate 
treatment, suboptimal observation of 
drug intake) as major determinants of 
death needs further evaluation. The 
appearance of XDR TB in western Eu-
rope conﬁ  rms that poor management 
and poor infection control in congre-
gate settings exist and that new rapid 
diagnostic tests and new drugs are ur-
gently needed. 
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Buruli Ulcer, 
Nigeria
To the Editor: Buruli ulcer (BU), 
a neglected tropical disease caused by 
Mycobacterium ulcerans, is character-
ized by necrosis of subcutaneous tis-
sue, leading to chronic, painless, and 
progressive ulcers. Without proper 
treatment, BU results in severe and 
permanent disability in more than a 
quarter of patients. Most patients are 
children <15 years of age. BU has 
been reported in >30 countries (1). The 
World Health Organization (WHO) 
has described the epidemiology, clini-
cal features, diagnosis, and treatment 
of BU (1–3).
In 1967, Gray et al. described 
4 BU cases in the Benue River Val-
ley in Nigeria (4). The authors also 
described unpublished reports of the 
disease in Banbur, Adamawa State, 
in the upper part of the Benue River 
Valley. In 1976, Oluwasanmi et al. 
described 24 BU cases in and around 
Ibadan (5). Since then, there has been 
no ofﬁ  cial report of BU in Nigeria. 
However, unofﬁ  cial reports indicate 
that the disease is still present in the 
country. For example, between 1998 
and 2000, BU cases from the Lep-
rosy and Tuberculosis Hospital in 
Moniaya-Ogoja, Cross River State, 
were bacteriologically conﬁ  rmed  at 
the Institute of Tropical Medicine in 
Belgium (6). More recently, patients 
from Nigeria have been treated in the 
neighboring countries of Benin (7) 
and Cameroon (8).
To clarify the BU situation in Ni-
geria, the government, with technical 
assistance from WHO, carried out a 
rapid assessment in the southern and 
southeastern states of the country, 
where cases had been previously re-
ported. Preassessment sensitization 
workshops for health workers within 
the selected states were held in June 
and July 2006. The assessment took 
place November 15–19, 2006. The 
team, which was made up of interna-
tional experts and national and state 
health ofﬁ   cials, was divided into 2 
groups. Group A visited Akwa Ibom 
and Cross Rivers States, and group B 
visited Anambra, Ebonyi, and Enugu 
States.
Based on the WHO case deﬁ  ni-
tions (1), 14 of 37 patient examined 
were considered likely to have BU (9 
active and 5 inactive cases); 9 were 
children <15 years of age. Eight pa-
tients were female, and 6 were male. 
One of the patients with active disease 
had the edematous form, 1 had osteo-
myelitis and ulcer, and the other 7 had 
ulcers (Figure). Ten of the patients 
had lesions on the lower limbs, 3 on 
the upper limbs, and 1 on the face. All 
cases were documented by registra-
tion on a modiﬁ  ed version of the BU 
02 form (1) and photography. Swab 
specimens were taken from all active 
ulcerative lesions. A ﬁ  ne-needle  as-
piration technique was used to obtain 
specimens from the edematous pa-
tient. In 4 (44%) of the 9 patients with 
active cases, the clinical diagnosis was 
conﬁ  rmed by the IS2404 PCR at the 
Institute of Tropical Medicine.
The locations and number of 
cases identiﬁ  ed in each are as follows: 
Iﬁ  te Ogwari village, Ayamelum Local 
Government Area (LGA), Anambra 
State (4 cases); Ndo Etok village, Ogo-
ja LGA, Cross River State (3 cases); 
Nkpo Hamida village, Igbo-Eze North 
LGA, Enugu State (1 case); Iburu vil-
lage, Ohaozora LGA, Ebonyi State 
(1 case); Akofu village, Ikwo LGA, 
Ebonyi State (1 case); Amagunze vil-
lage, Nkanu East LGA, Enugu State 
(1 case); Okro Mbokho village, East-
ern Obolo, Akwa Ibom State (1 case); 
Oron village, Oron LGA, Akwai Ibom 
State (1 case); and Ugwu Tank, Awka 
South LGA, Anambra State (1 case).
In conclusion, 30 years after the 
last publication (5) of cases in south-
western Nigeria, BU cases have been 
found in the southern and southeastern 
parts of the country. A similar phenom-
enon occurred in Cameroon, where 
a case search in 2001 in 2 districts 
where cases had last been reported 24 